Qaasid News

Download Our App

Category: 3. Business

  • Using AI to Differentiate Primary Lung Squamous Cell Carcinomas From Metastases

    Using AI to Differentiate Primary Lung Squamous Cell Carcinomas From Metastases

    A multipronged artificial intelligence (AI)–assisted approach integrated into routine molecular profiling identified 3.1% of cases submitted as lung squamous cell carcinoma as metastases from other origins, revealing a meaningful rate of misdiagnosis in this patient population, according to a cross-sectional study published by Evans et al in JAMA Network Open. 

    “Distinguishing primary lung squamous cell carcinoma from squamous metastases to the lung is a clinical challenge due to histopathologic similarities,” the investigators wrote. “Accurate diagnosis is essential to guide treatment decisions.”

    They also commented, “These findings suggest the importance of an AI-assisted approach to distinguishing tissues of origin in patients with presumed primary lung squamous cell carcinoma, thus avoiding misdiagnosis and associated impacts on prognosis and therapy selection.”

    Study Details

    This study leveraged GPSai, a tissue-of-origin AI model automatically applied to each sample submitted for molecular profiling, to identify potential misdiagnoses among research-eligible cases initially classified as lung squamous cell carcinoma. Molecularly profiled cases from the Caris Life Sciences clinicogenomic database, spanning January 2024 to January 2025, were analyzed, and all cases underwent review by board-certified pathologists.

    The primary outcome was the misdiagnosis rate among presumed lung squamous cell carcinomas, confirmed through pathologist review and orthogonal evidence. This included clinical history and findings, GATA3 and uroplakin II immunohistochemistry for urothelial carcinoma, ultraviolet variant signature for cutaneous squamous cell carcinoma, CD5 and CD117 (c-KIT) immunohistochemistry for thymic carcinoma, and human papillomavirus positivity for orogenital squamous cell carcinoma (eg, head and neck, cervical).

    Key Findings

    Using a combination of AI and orthogonal evidence, 123 of 3,958 cases (3.1%) initially diagnosed as presumed lung squamous cell carcinoma were confirmed as misdiagnoses, with affected patients having a median age of 71 years and 76.4% being male.

    The cohort comprised 50 cutaneous squamous cell carcinomas (40.7%), 33 orogenital squamous cell carcinomas (26.8%)—including 25 in the head and neck (75.8%)—20 urothelial carcinomas (16.3%), 15 thymic carcinomas (12.2%), 4 nuclear protein in testis carcinomas (3.3%), and 1 prostate squamous cell carcinoma (0.8%).

    Clinical history or findings consistent with the revised diagnosis were present in 92 of 123 patients (74.8%). In 88 cases (71.5%), first-line systemic therapy recommendations per guidelines changed following reclassification.

    “This cross-sectional study of patients diagnosed with lung squamous cell carcinoma found that an AI-assisted approach integrated into the routine molecular profiling workflow identified a meaningful number of misdiagnoses,” the investigators concluded. “Comprehensive evaluation of orthogonal evidence supported these diagnosis changes, which had important implications for prognosis and therapy selection.”

    Hassan Ghani, MD, of Caris Life Sciences, Phoenix, is the corresponding author of the article in JAMA Network Open.

    Disclosure: The study was funded by Caris Life Sciences. For full disclosures of the study authors, visit jamanetwork.com.

    Continue Reading

  • Stock market today: Live updates

    Stock market today: Live updates

    Traders work on the floor of the New York Stock Exchange.

    NYSE

    U.S. stock futures fell on Thursday, weighed by higher oil prices, as traders followed the latest developments out of the Middle East.

    Futures tied to the Dow Jones Industrial Average fell 413 points, or 0.9%. S&P 500 futures and Nasdaq 100 futures shed 0.9% and 1.1%, respectively.

    Crude prices rose on Thursday, putting pressure on equities. Brent futures jumped 3.8% to $106.07 per barrel. West Texas Intermediate futures climbed 3.5% to $93.45.

    President Donald Trump said in a Truth Social post that Iran “better get serious soon, before it is too late, because once that happens, there is NO TURNING BACK, and it won’t be pretty.” Trump also labeled Iranian negotiators as “very different” and “strange,” claiming they were “begging” the U.S. to make a deal to end the now four-week war.

    This comes after Iran’s foreign minister reportedly told state media on Wednesday that top authorities in the Middle Eastern nation are reviewing an American proposal to end the war, but Tehran has no intention of having talks with the U.S.

    Meanwhile, Gulf countries issued a joint statement Thursday condemning Iran’s “criminal” strikes on their energy infrastructure. They added that they are ready to defend themselves going forward.

    “While we value our fraternal relations with the Republic of Iraq, we call on the Iraqi government to take the necessary measures to immediately halt the attacks … toward neighboring countries,” the joint statement said.

    Wall Street is coming off a winning session, putting the major averages on track for a winning week, even in the face of the contradictory statements made by the U.S. and Iran regarding peace talks between the two sides.

    Tobin Marcus, head of U.S. policy and politics at Wolfe Research, believes the recent market moves signal that investors are betting Iran is the one that could be “lying.”

    Markets “seem to be concluding that Iran’s negative public message may be a smokescreen for a more accommodating private posture,” he wrote in a note. “We’re not so sure, and the ambiguity can’t last much longer amid Trump’s 5-day deadline for talks.”

    — CNBC’s Kevin Breuninger contributed reporting.

    Continue Reading

  • ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026 – ImmunityBio

    1. ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026  ImmunityBio
    2. ImmunityBio Gains on Anktiva Approval in Macau, First in Asia | 2026 – News and Statistics  IndexBox
    3. ImmunityBio’s Global Expansion Raises Stock Speculation  timothysykes.com
    4. Nogapendekin Alfa/BCG BLA Resubmitted For NMIBC Population  CancerNetwork
    5. Christopher Pieczonka, MD, discusses early data on NAI plus BCG in BCG-naïve NMIBC  Urology Times

    Continue Reading

  • Maersk Recognised as a Leader in the 2026 Gartner® Magic Quadrant™—5 Years Running

    Maersk Recognised as a Leader in the 2026 Gartner® Magic Quadrant™—5 Years Running

    For the fifth year in a row, A.P. Moller – Maersk has been recognised as a Leader in the 2026 Gartner Magic Quadrant™ for Third-Party Logistics (3PL) report, a report that positions vendors for their Completeness of Vision and Ability to Execute.

    The market definition

    Gartner defines a third-party logistics (3PL) provider as “a logistics service provider that moves, stores and manages the flow and distribution of products and materials on behalf of its customers for a fee without taking ownership. The 3PL will typically provide and manage operations that must include warehousing, transportation or value-added services that can be scaled and customized to the shipper’s needs. 3PL providers solve the challenge of efficiently managing the movement, storage and distribution of goods by enabling companies to outsource complex logistics operations, thereby reducing operational costs, improving supply chain visibility and supporting business scalability.”

    Critical capabilities for a Third-Party Logistics Provider (3PL)

    “The Critical Capabilities research, a companion piece to the Magic Quadrant for Third-Party Logistics, is an evaluation of third-party logistics providers based on seven key capabilities across four major use cases.”

    All the above details are taken from the Magic Quadrant for Third-Party Logistics, published on March 5, 2026.

    GARTNER, Magic Quadrant for Third-Party Logistics, Chris Kina, Matthew Beckett, et al., 5 March 2026.

    Gartner, Critical Capabilities for Third-Party Logistics, Chris Kina, Matthew Beckett, et al., 9 March 2026

    Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER and MAGIC QUADRANT are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission.
    All rights reserved.

    Be ready for logistics to go all the way! Discover more with Maersk Logistics Insights, and learn more about , or for more logistics trends and insights, read and download The Logistics Trend Map.

    Continue Reading

  • Blackstone, Raya Holding, NRT and Sightline Announce Partnership to Invest in UAE Payments Infrastructure Platform

    Blackstone, Raya Holding, NRT and Sightline Announce Partnership to Invest in UAE Payments Infrastructure Platform

    New York, NY and Abu Dhabi, UAE – March 26, 2026 – Blackstone (NYSE: BX), the world’s largest alternative asset manager, today announced that funds managed by Blackstone (“Blackstone”) have invested US$250 million in Advanced Digital Gaming Technology (“ADGT”), a newly established payments and data intelligence technology platform launched from the United Arab Emirates to support regulated digital markets globally.

    ADGT has been established through a strategic partnership between Blackstone, Raya Holding, the Abu Dhabi-based investment company, and leading technology partners NRT Technology and Sightline Payments.

    Headquartered in Abu Dhabi, ADGT is positioned at the crossroads of global finance, high growth markets, and next-generation digital infrastructure. The company plans to initially focus on deployments across the UAE, the Middle East, Africa, and select international corridors. In the UAE, ADGT is the premier payments and compliance technology provider to the commercial gaming market, which is projected to become one of the fastest-growing regulated markets globally: ADGT is currently the only licensed platform able to contract directly with both land-based venues and online digital platforms, enabling a unified experience for both consumers and operators.

    Michael Dominelli, CEO of ADGT, said: “ADGT was created in the UAE from the ground up to serve as a new global standard for financial payments technology. Built upon modern infrastructure, and with a strong institutional and regulatory framework, we have created a platform that is designed, built, governed and experienced with resilience and scalability in mind. With the backing of Blackstone, Raya Holding and the leading payments technology partnerships, we have the scale, resources and credibility to create a global success story engineered and headquartered in the UAE.”

    Jon Gray, President and Chief Operating Officer, Blackstone, said: “We see significant opportunity to deploy capital at scale in the UAE to build companies that can grow both domestically and internationally, despite near term headwinds. The UAE is a global leader in travel and leisure, with emerging strength in technology, and we are excited to support ADGT to capitalize on these powerful trends.”

    H.H. Sheikh Mohammed Bin Sultan Bin Khalifa Bin Zayed Al Nahyan said: “ADGT reflects the UAE’s long-term vision to lead in the development of next-generation financial technology and regulated digital infrastructure. With a progressive regulatory framework and strong institutional support, the UAE continues to create an environment where global technology platforms can be built and scaled. Through this partnership with Blackstone, and the integration of proven technology capabilities from NRT Technology and Sightline, ADGT is positioned to establish a new benchmark for regulated payments infrastructure. From Abu Dhabi, we are developing a platform designed not only to serve the UAE, but to support the evolution of regulated digital markets globally.”

    The platform is designed to support national-scale deployments, cross-border interoperability, and evolving regulatory frameworks. ADGT integrates digital wallets, real-time funding and payout rails, identity and access management, compliance monitoring, and both closed-loop and open-loop ecosystem controls within a single interoperable infrastructure supporting both on-property transactions and digital engagement.

    Blackstone has had a presence in the UAE since 2010. The firm’s investments in the country include GLIDE, a pan-GCC logistics platform developed in partnership with Lunate, and Property Finder, the leading UAE real estate marketplace.

    Kirkland & Ellis LLP, Brownstein Hyatt Farber Schreck LLP and Alaeddini & Co acted as legal advisors to Blackstone, whilst Morgan Lewis & Bockius LLP’s Abu Dhabi office acted as legal advisors to ADGT.

    About Blackstone
    Blackstone is the world’s largest alternative asset manager. Blackstone seeks to deliver compelling returns for institutional and individual investors by strengthening the companies in which the firm invests. Blackstone’s $1.3 trillion in assets under management include global investment strategies focused on real estate, private equity, credit, infrastructure, life sciences, growth equity, secondaries and hedge funds. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, X (Twitter), and Instagram. 

    About Raya Holding
    Raya Holding is an Abu Dhabi-based investment company focused on building and scaling strategic platforms across high-growth sectors including financial technology, digital infrastructure, consumer markets and emerging industries. Led by H.H. Sheikh Mohammed Bin Sultan Bin Khalifa Al Nahyan, the firm partners with global institutions, operators and technology leaders to develop businesses with long-term growth potential and international reach. Raya Holding’s investment strategy focuses on supporting innovation, enabling market expansion and creating sustainable value through strategic partnerships.

    About NRT Technology
    Since 1993, NRT Technology has been changing the game as the world’s largest payment technology company in gaming. NRT’s solutions improve efficiency, enhance security, and empower casinos to deliver exceptional guest experiences through the fastest, safest, and smartest financial and engagement technologies in the industry. From the back office to the casino floor, NRT’s innovations have redefined how the gaming world operates. With a commitment to driving performance, maximizing revenue, and exceeding expectations, NRT continues to set – and redefine – the industry standard.

    About Sightline
    Sightline is transforming the gaming industry with its innovative suite of award-winning digital payment and wallet solutions. Through its expertise in consumer behavior, payments technology, and software development, Sightline is uniquely positioned to help casino resorts and online gaming companies offer a more robust, customer-centric omnichannel experience. Sightline’s flagship product, Sightline Pay, enables players to use a single digital payment method across all gaming channels and throughout the entire resort. It’s currently the preferred payments and cashless solution for more than 50 partners in 44 states.

    Forward-Looking Statements
    This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect Blackstone’s current views with respect to, among other things, its operations, taxes, earnings and financial performance and the strategic partnership referred to herein. You can identify these forward-looking statements by the use of words such as “outlook,” “indicator,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “seeks,” “approximately,” “predicts,” “intends,” “plans,” “scheduled,” “estimates,” “anticipates,” “opportunity,” “leads,” “forecast,” “possible” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Blackstone believes these factors include but are not limited to those described under the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in its subsequent filings with the United States Securities and Exchange Commission (“SEC”), which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in its other subsequent filings. The forward-looking statements speak only as of the date of this release, and Blackstone undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

    Blackstone Contacts

    Dafina Grapci-Penney
    [email protected]

    Felix Lettau
    [email protected]
    +44 75870 20020


    Continue Reading

  • Porsche Design opens new timepieces manufactory in Switzerland

    Porsche Design opens new timepieces manufactory in Switzerland

    Auf einen Blick

    • Porsche Design has opened its new watch manufacture in Switzerland, underscoring the brand’s long-term commitment to the Timepieces segment.
    • The historic building has been extensively modernised and now offers state-of-the-art technology, increased production capacities and optimal working conditions.
    • The new “transparent manufacture” serves both as a production facility and an experiential brand space, where guided tours are now also available.

    With the relocation from its previous production site in nearby Solothurn to the new manufactory, the company now establishes its first permanent operational base in one of the most traditional regions of Swiss watchmaking. The historic building was acquired in spring of 2024, completely modernized within just 18 months, and precisely tailored to the specific requirements of Porsche Design. The result is a competence center that marks the next stage in the development and production of exclusive mechanical Timepieces.





    The ceremonial opening also represents a milestone for Porsche AG, the parent company of Porsche Design. As the only automotive brand with its own watch manufactory, Porsche emphasizes its long-term engagement to the business sector Timepieces and to the development of high-quality, technically sophisticated watches distinguished by unmistakable sports car–inspired design.

    Three years of planning and construction for a long-term vision

    Over a total period of three years – from the initial inspection of the then vacant building to the move into the completed manufactory – a holistic concept for an in-house production facility was realized, translating the design and technological DNA of Porsche into the art of mechanical watchmaking. Materials, engineering and design all follow a clear principle: form and function in perfect symbiosis. “Swiss Made” is therefore not merely a promise of origin, but an expression of uncompromising quality standards and an integral part of the brand’s DNA.

    Porsche Design Timepieces Manufactory, Grenchen, Switzerland, 2026, Porsche Design





    “With the opening of our new Timepieces Manufactory in Grenchen, we are entering a new chapter for Porsche Design Timepieces. This investment is a clear commitment to the Timepieces division and an expression of our entrepreneurial mindset to further expand this area,” says Matthias Becker, Member of the Executive Board for Sales and Marketing at Porsche AG and Chairman of the Advisory Board of the Porsche Lifestyle Group. “As the first automotive manufacturer operating its own watch manufactory, we derive a clear ambition from this: to offer our customers exceptional Timepieces that combine innovation, precision and a high degree of customization in true Porsche fashion.“

    At the heart of this strategic direction lies customization. Custom-built Timepieces form the centerpiece of the portfolio. In the manufactory, precisely crafted one-of-a-kind watches are created – configured according to the personal preferences of each customer. Much like the configuration of a sports car, every model combines engineering excellence and functionality within a clear, reduced design language.

    “For us, Grenchen is far more than a production site. In this historic building, we are giving the vision of our founder F. A. Porsche a home. Here, we bring together all of our expertise to develop and manufacture mechanical timepieces that set new benchmarks in innovation and customization. Every watch embodies this philosophy – consistently designed, technically sophisticated and crafted with the same passion as a sports car from Zuffenhausen,” says Rolf Bergmann, CEO of the Porsche Design Timepieces Manufactory. The decision to locate the facility in the heart of the Swiss watchmaking triangle also follows a clear long-term strategy. The region offers a unique ecosystem of specialized suppliers and highly skilled experts. By consolidating all key technical functions – from development, engineering and assembling to quality management and after-sales services – Porsche Design further strengthens its expertise across the value chain.

    Modern technology, increased capacities, ideal conditions

    The historic building has been comprehensively modernized and functionally restructured. Covering a total area of approximately 3,600 square meters, the facility currently offers ten state-of-the-art watchmaking stations. The clear, symmetrical architecture and bright, open interior design create a working environment meticulously tailored to the demands of precision mechanical production. A specially developed lighting concept simulates constant daylight throughout the entire space. This base illumination is complemented by individually adjustable LED lights at each workstation, enabling even the finest dust particles or minimal surface deviations to be reliably detected – at any time of day or year.

    Production, Porsche Design Timepieces Manufactory, Grenchen, Switzerland, 2026, Porsche Design





    Constant climatic conditions are essential for the production of mechanical Timepieces. Accordingly, the manufactory features an ISO 7 cleanroom with watchmaking benches at ISO 5 level. An advanced ventilation system with five air changes per hour, controlled humidity between 40 and 50 percent, and overpressure technology ensures maximum cleanliness and stability. Access is granted exclusively through a dedicated airlock and with protective clothing, maintaining optimal conditions at all times.

    Production, Porsche Design Timepieces Manufactory, Grenchen, Switzerland, 2026, Porsche Design





    The production area is organized according to clearly defined process flows and follows the Porsche production principle of sequential manufacturing, with short distances and efficient just-in-time logistics. An integrated gravity-fed conveyor system connects the logistics area directly to the cleanroom without additional access points – a technical solution that combines efficiency with the highest safety standards.

    Conveyor system, Porsche Design Timepieces Manufaktactory, Grenchen, Switzerland, 2026, Porsche Design





    In addition to production, the building houses development, quality management, after-sales services, and central administrative functions. For employees in administrative roles, spacious, bright, and climate-controlled offices with modern workstations and conference rooms have been created. Social spaces, including break rooms and a staff kitchen, meet the latest standards, providing room for personal interaction and professional exchange.

    Production, Porsche Design Timepieces Manufactory, Grenchen, Switzerland, 2026, Porsche Design




    Production, Porsche Design Timepieces Manufactory, Grenchen, Switzerland, 2026, Porsche Design




    ”In our new manufactory, we follow the principle of ‘not more, but better’,” emphasizes Rolf Bergmann. “Precision begins with the architecture and design of the building. Only those who find state-of-the-art working conditions in production, logistics, and administration can achieve peak performance. The journey from the first idea to the finished product leaving the manufactory – and beyond – is long. It was essential that we create the ideal conditions for each discipline. Only then does every gear engage perfectly with the next – like in a Swiss movement.”

    Sustainability aspects are key elements of both the construction and operational concept of the manufactory. From the outset, the focus was on energy efficiency and resource-conscious operation. On the roof, a modern photovoltaic system with 211 solar panels and a peak output of 134 kW generates up to 62 percent of the facility’s energy needs. A high-performance heat pump supports efficient heating and cooling processes, while a ventilation system with heat recovery further reduces energy consumption. This attention to efficiency continues down to the fixtures in the entire building, which are designed to supply only cold water by default, avoiding unnecessary energy use.

    A long history in the heart of the Swiss watch industry

    The search for a new manufactory building began in 2020, as it became clear that the production capacity of the former manufactory in Solothurn would no longer suffice in the long term and further expansion on site was not possible. After a thorough evaluation of numerous options, the choice fell on the historic building in Grenchen – not only because of its strategically advantageous location but also due to its special connection to Porsche Design. Built in 1955 and once the home of the renowned timepieces brand Eterna, the new manufactory boasts a long and influential history. In 1995, the building was acquired by F. A. P. Beteiligungen GmbH, a company that Professor Ferdinand Alexander Porsche and his son were involved in. Between 1998 and 2014, Porsche Design watches were manufactured here under license from Eterna.

    The decision to establish a dedicated manufactory reflects an attitude that has always defined Porsche: the determination to realize the highest standards in-house. What Ferry Porsche once articulated for sports cars also applies to watchmaking – if what is desired does not exist, it must be developed independently. In 1972, F. A. Porsche transferred this approach to the world of timepieces, laying the foundation for the design DNA of Porsche Design.

    F. A. Porsche, Porsche Design Timepieces Manufactory, Grenchen, Switzerland, 2026, Porsche Design





    “We evaluated numerous potential locations. Our guiding principle was to carry forward the philosophy of Ferry Porsche – after all, the manufactory is only the third in-house production site of Porsche. In doing so, we applied the same precision and care as we do with our timepieces, creating the specific conditions necessary for our manufacturing,” says Rolf Bergmann.

    Respect for tradition meets modernity

    The manufactory brings together historic substance with contemporary architecture and technology. Particular care was taken to preserve and sensitively restore selected historic elements. In the listed meeting room, surface finishes and stucco details were meticulously restored with artisanal precision to retain the original character. The original vault doors from 1956 were also technically refurbished while preserving their visual appearance – an element that underscores the respect for the building’s history. Clean lines, bright spaces and functional structures create a modern production environment while reflecting the design principles of Porsche Design. Subtle accents – such as a staircase handrail upholstered in original Porsche interior leather in carmine red – reference the brand’s roots in automotive design.

    The “Glass Manufactory“ – Experiencing Timepieces

    The new manufactory serves both as a production facility and as a brand experience space. On the ground floor, an exhibition and event area traces the evolution of Porsche Design Timepieces since 1972. Historical exhibits and curated archival pieces bring the connection between automotive design and watchmaking to life.

    The configuration area, known as the Fitting Lounge, offers customers the opportunity to design a custom-built Timepiece directly on site and collect it there following its individual production. For the first time, configuration, manufacturing, and handover take place under one roof.

    Custom Built Fitting Lounge, Porsche Design Timepieces Manufactory, Grenchen, Switzerland, 2026, Porsche Design





    The concept is complemented by lounge areas and flexible event spaces that provide room for encounters and presentations. A particular highlight is the possibility for customers to drive their Porsche directly into the manufactory, creating a unique way to experience the connection between automobile and timepiece. From the very beginning of the planning process, the concept of transparency through a “glass manufactory” was a key guiding principle. It enables guided factory tours – a tradition long associated with Porsche – now offering Porsche Design customers an exclusive insight into the highly specialized world of watchmaking.

    A focus on long-term and organic growth

    With its clearly defined technological and organizational approach, Porsche Design is laying the foundation for the sustainable development of its timepieces business. The manufactory in Grenchen is designed for long-term, organic growth: scalable processes and potential additional capacities provide the flexibility required to implement future development steps. “Our perspective is long-term. With the manufactory in Grenchen, we are creating the foundation for the next generation of Porsche Design Timepieces. It is less about scale and more about substance – about innovation, maximum customization, and technical excellence,” says Rolf Bergmann. With the new manufactory in Grenchen, Porsche Design is establishing a strong foundation for the future.

    Continue Reading

  • Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco

    Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco

    • Research reveals an industry mindset shift towards ‘undetectable†‘ aesthetics, as people seek a natural-looking, personalized approach and a subtle, rejuvenated appearance that is almost imperceptible1,2,‡
    • Leading healthcare professionals discussed the findings at an Allergan Aesthetics* event at AMWC, which reaffirm ‘undetectable’ aesthetics, and the positive role of HA injectables in helping to achieve a discreet ‘look’1,2,§
    • The latest findings are part of Allergan Aesthetics’ ongoing commitment to quality education and helping shape the future of HA injectables
    • Together with trusted healthcare practitioners, the JUVÉDERM® Collection of Fillers is committed to advancing a new era of HA injectables.

    NORTH CHICAGO, Ill., March 26, 2026 /PRNewswire/ — Allergan Aesthetics, an AbbVie company, a global leader in medical aesthetics treatments and manufacturers of the market-leading JUVÉDERM® Collection of Fillers,3,4,‖ is once again forging ahead and has announced that the ‘Undetectable† Era’ will drive the next chapter in the Hyaluronic Acid (HA) injectable category at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) 2026 in Monaco.

    For over 20 years, HA injectables have been a trusted, versatile, and clinically proven foundation of modern aesthetics.5-28, ¶,‖,††,‡‡ §§ Today, the category and the aesthetics landscape are changing.1 Research findings discussed at an Allergan Aesthetics event at the congress identify the shift towards an ‘undetectable era’ of aesthetics and the role HA injectables play in helping to achieve natural-looking outcomes.1

    The notion of ‘undetectable’ aesthetics appeals to a dominant new wave of patients who are choosing to take a longevity-based approach to ageing1. Through its market-leading portfolio of HA injectables3,4,‖, JUVÉDERM® is helping to meet these consumer expectations head on. Showcasing safety, high quality design, consistent outcomes, and versatility, JUVÉDERM® offers a comprehensive solution for the modern beauty consumer.17-27,29-32

    Understanding the ‘Undetectable’ Aesthetics Era
    This ‘undetectable’ era refers to a shift in aesthetic procedures towards patients seeking results that are subtle, natural-looking, leave no obvious traces of treatment, and are only noticeable to themselves and close acquaintances.1,33 The research reveals that today’s patients don’t want to look treated, they want a natural look.1,2,33,‡ This shift has already been seen in celebrity circles and amongst influencers appearing to adopt the approach with almost imperceptible aesthetic enhancements.33,34

    This ‘undetectable’ look relies on a carefully considered approach; product, quantity, and placement is key, and practitioners must employ a holistic strategy that centers around a full-face consultation. With the right product in expert hands, JUVÉDERM®‘s portfolio of versatile, patented HA injectables can help achieve a refreshed, lifted, natural look, with almost imperceptible results that define the ‘undetectable’ aesthetics era.7-13,17,35-38, ¶¶,#,**

    “Natural-looking for me means preserving the patient’s beauty. And that’s exactly why I love the word ‘undetectable.’ I fully welcome the new ‘undetectable era’, because to achieve an undetectable look, it’s important to respect the aging process and provide a natural-looking result,” says Dr Juliana Chieppe, a worldclass dermatologist from Brazil who was interviewed for the research and discussed the findings on the panel at the congress.

    Global Patient Demand for ‘Undetectable’ Aesthetics

    Layered Beauty: The New Aesthetic Mindset, is a new report launched by Allergan Aesthetics at AMWC 2026, which aims to help healthcare professionals better understand consumer needs and behaviors. The report further uncovered the shift towards ‘undetectable’ aesthetics. Key findings from global research39 across more than 12,000 beauty-involved consumers in nine countries found that:

    • 74% like their aesthetic results to look undetectable39
    • 71% worry about looking fake or overdone39
    • 85% like results that look natural and subtle39
    • 84% prefer products and/or treatments that give a natural-looking appearance39
    • 81% value personalized plans designed for their face and aesthetic needs39

    The Role of the Practitioner and HA Injectables in the ‘Undetectable’ Aesthetics Era

    As healthcare practitioners will attest, a truly individual outcome, definitive of the ‘undetectable’ era, begins with the consultation.1,35,40,41 With Allergan Aesthetics’ versatile JUVÉDERM® Collection of Fillers, practitioners can combine their expert knowledge and innate artistry to deliver each patient’s interpretation of natural-looking beauty.7-14,42-45, ¶¶,**,# These healthcare providers leverage injection techniques that are strategically placed to lift, balance, restore volume, and enhance, and play an integral role in the ‘undetectable’ aesthetics era.7-14,17,35-38,40,46 HA injectables can create personalized effects that are long-lastingΩ, naturally fade with time, and can provide a refreshed look.7-14,24-26,31,32,35,40,47,48

    “HA Injectables can be tailored for the patient’s needs, in addition to being supported with science-based data and a well-established safety profile and being reversible. Some injectables are ‘one size fits all’, and don’t offer the precise tailoring of the amount that is possible with HA injectables,” says Dr Juliana Chieppe.1,7-13,15-20,23-28,30,31

    Mark Wilson, Senior Vice President at International Allergan Aesthetics said, “In a world where ‘natural’ is almost impossible to define, we herald this new ‘undetectable’ era, which provides the language for patients to communicate, and practitioners to understand, that patients still want to look like themselves, just more glowing, healthy, and rested. Patients are seeking personalized and almost imperceptible enhancements that complement their natural features. JUVÉDERM®‘s market-leading collection of HA injectables offers our practitioners the versatility to help patients achieve results that are aligned with the best version of themselves, as sought after in this ‘undetectable’ aesthetics era.” 7-14,35,36

    How Allergan Aesthetics Helps Practitioners Meet Modern Patient Goals

    While the notion of ‘undetectable’ aesthetics demands the highest quality product, it cannot be achieved authentically without referencing and respecting a patient’s individuality. Allergan Aesthetics champions the individual approach and versatility of HA injectables and is paving the way for multimodal treatments with its innovative AA SignatureTM treatment approach.7-14,35,41,47,48 AA SignatureTM is designed to support healthcare professionals in meeting modern patient goals by using Allergan Aesthetics’ advanced, versatile portfolio of products including the JUVÉDERM® Collection of Fillers.7,8,46,49-54

    Whether used alone or synergistically with other modalities as part of a multi-layered facial harmonization plan, HA injectables elevate and enhance other treatments, delivering powerful, personalized results.7-14,17,35-38,40,46,¶¶,**

    For decades, JUVÉDERM® has led the non-invasive aesthetics market with a collection of HA injectables that help patients achieve desirable, long-lastingΩ results.5,6,24-26,30,31,47,48,‖

    Whether the focus is restoring volume, improving facial contours, or balancing proportions, JUVÉDERM®‘s HA injectables allow practitioners to enhance or augment specific areas of the face based on patients’ aesthetic goals and unique anatomy, supporting a patient’s individuality.7-14,17,35-38,40,46, ¶¶,**,# 

    With the ‘undetectable’ era set to dominate the beauty landscape in 2026, the power of HA injectables has never been more clear.1 Able to refine, define, and balance natural facial characteristics with efficacy, safety, and versatility, JUVÉDERM® reaffirms its central role in the future of holistic ageing and supporting subtle, natural-looking¶¶,**,# results.7-14,17-28,30-32,35-38, ††,‡‡,§§, ¶¶,**,#

    Celebrating 10 Years of MD CodesTM at AMWC
    To celebrate more than 10 years of MD CodesTM, Allergan Aesthetics is launching Dr. Mauricio de Maio’s new book: MD CodesTM: A Decade of Excellence—a compendium of real-world experience and dedication to providing a holistic approach to facial harmony.

    It’s an extensive collection of 34 clinical case studies with before and after imagery. It is also a detailed resource for healthcare professionals, as it demonstrates the transformative results made possible by using MD CodesTM with JUVÉDERM® and the wider injectables portfolio from Allergan Aesthetics.

    Allergan Aesthetics is strongly committed to the health, safety, and well-being of the practitioners and patients who put their trust in its products. As part of the company’s ongoing commitment to medical education, Allergan Aesthetics offers training programs for appropriate healthcare professionals on the use of JUVÉDERM® to help ensure optimal patient satisfaction and outcomes.

    Healthcare professionals can download the new report Layered Beauty: The New Aesthetic Mindset at https://global.allerganaesthetics.com/global-insights/layeredbeauty.

    Notes to Editors 

    About Allergan Aesthetics Future of HA Injectables research
    Allergan Aesthetics is heralding the era of ‘undetectable’ aesthetics, informed by its international research involving HCP interviews, consumer insights, industry reports, and social listening intelligence.

    ‘Undetectable’ refers to an aesthetic aspiration towards subtle, natural-looking, and discreet outcomes, rather than a definitive result.

    To assess the current and future landscape for HA Injectables, VML conducted the following analysis on behalf of Allergan Aesthetics1:

    • Comprehensive review of Allergan Aesthetics’ proprietary global research, encompassing qualitative, quantitative, and existing social intelligence into HA injectables focused on the category, consumers, and HCPs.
    • To understand patient and HCP conversation around HA injectables in Brazil, Thailand, and the United Kingdom, custom social listening intelligence research was conducted using the Talkwalker platform for the period January 2024 to June 2025. A further custom social listening exercise was conducted in China for the same period using the Wisers platform in August 2025.
    • In-depth interviews with ten HCPs in Brazil, Canada, China, Thailand, and the UK were conducted in September 2025, including Dr. Babak Esfahani, Plastic & Aesthetic Surgeon (Germany), Dr. Apul Parikh, Aesthetic Doctor (UK), and Dr. Juliana Chieppe, Dermatologist (Brazil), who will form part of the panel at AMWC.

    About Layered Beauty: The New Aesthetic Mindset
    To better understand how today’s culture is reshaping aesthetic decision-making, Allergan Aesthetics commissioned a large-scale global research study spanning nine countries (Canada, United States, United Kingdom, China, Brazil, France, Germany, Thailand, and KSA) and more than 12,286 beauty-involved consumers. The study explored evolving attitudes, treatment behaviors, and expectations around combination and multimodal approaches to aesthetics, revealing a clear shift away from isolated, single interventions towards the need for integrated, personalized treatment plans delivered over time. This research was undertaken to help Allergan Aesthetics better understand these changing behaviors and support the development of structured approaches to treatment such as AA Signature™, reflecting how patients now approach aesthetics. The research was carried out in November and December 2025.

    About AbbVie
    AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube.

    About Allergan Aesthetics
    At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit. www.allerganaesthetics.com.

    JUVÉDERM® Collection of Fillers Important Information
    INDICATIONS
    JUVÉDERM® VOLUMA® XC injectable gel is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face, for augmentation of the chin region to improve the chin profile, and for supraperiosteal injection to augment the temple region to improve moderate to severe temple hollowing in adults over the age of 21.
    JUVÉDERM® VOLUX® XC injectable gel is indicated for subcutaneous and/or supraperiosteal injection for improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition.
    JUVÉDERM® VOLLURE® XC injectable gel is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in adults over the age of 21.
    JUVÉDERM® VOLBELLA® XC injectable gel is indicated for injection into the lips for lip augmentation and correction of perioral rhytids, and for the improvement of infraorbital hollowing in adults over the age of 21.
    JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC injectable gels are indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).
    JUVÉDERM® Ultra XC injectable gel is also indicated for injection into the lips and perioral area for lip augmentation in adults over the age of 21.

    IMPORTANT SAFETY INFORMATION
    CONTRAINDICATIONS
    These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.

    WARNINGS

    • Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft tissue fillers; for example, after insertion of the needle and just before injection, the plunger rod can be withdrawn slightly to aspirate and verify the needle is not intravascular, inject the product slowly, and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur
    • Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled

    PRECAUTIONS

    • To minimize the risk of potential complications, these products should only be used by healthcare professionals who are knowledgeable about the anatomy and the product(s) for use in indicated area(s), and who have appropriate training in facial anatomy, vasculature, safe injection techniques, and identification and management of potential adverse events, including intravascular complications
    • The potential risks of soft tissue injections should be discussed with patients prior to treatment to ensure they are aware of signs and symptoms of complications
    • The safety and effectiveness for the treatment of anatomic regions other than indicated areas for each product have not been established in controlled clinical studies
    • The safety for use of these products in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied
    • The safety for use during pregnancy and in breastfeeding females has not been established
    • The safety for use of JUVÉDERM® VOLUMA® XC has been established in patients between 35 and 65 years of age for cheek augmentation, 22 and 80 years of age for chin augmentation, and 32 and 82 years of age for improvement of temple hollowing
    • The safety for use of JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC in patients under 18 years, and the safety for use of JUVÉDERM® VOLUX® XC, JUVÉDERM® VOLLURE® XC, and JUVÉDERM® VOLBELLA® XC in patients under 22 years, has not been established
    • Dermal filler implantation carries a risk of infection. Follow standard precautions
    • Dermal fillers should be used with caution in patients on immunosuppressive therapy
    • Patients taking medications that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites
    • Patients who experience skin injury near the site of implantation may be at a higher risk for adverse events
    • If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment, or before skin has healed from a procedure prior to treatment, there is a possible risk of eliciting an inflammatory reaction at the injection site
    • The safety for use of JUVÉDERM® VOLUMA® XC injectable gel in patients with very thin skin in the mid-face has not been established
    • The safety of using a cannula with JUVÉDERM® VOLUMA® XC for cheek augmentation in patients with Fitzpatrick Skin Types V and VI or to improve temple hollowing has not been established
    • JUVÉDERM® VOLUMA® XC was not evaluated in subjects with significant skin laxity of the chin, neck, or jaw in the chin augmentation study
    • The effect of JUVÉDERM® VOLUMA® XC injection into the chin on facial hair growth has not been studied
    • Patients may experience late-onset adverse events with injectable gel implants, and late-onset nodules with use of JUVÉDERM® VOLUMA® XC
    • Based on preclinical studies, patients should be limited to 20 mL of any JUVÉDERM® injectable gel per 60 kg (132 lb) body mass per year. The safety of injecting greater amounts has not been established
    • Injection of more than 9 mL of JUVÉDERM® VOLUX® XC for improvement of jawline definition has not been studied

    ADVERSE EVENTS
    The most common reported side effects for JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA® XC, dryness was also reported. The majority were mild or moderate in severity. 
    To report an adverse reaction with any product in the JUVÉDERM® Collection, please call Allergan® Product Support at 1-877-345-5372. Please visit rxabbvie.com for more information.
    Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.

    DFU Links– added to end of ISI on HCP website
    Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-voluma-xc_dfu.pdf for JUVÉDERM® VOLUMA® XC
    Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-volux-xc_dfu.pdf for JUVÉDERM® VOLUX® XC
    Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-vollure-xc_dfu.pdf for JUVÉDERM® VOLLURE® XC
    Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-volbella_dfu.pdf for JUVÉDERM® VOLBELLA® XC
    Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-ultra-plus-xc_dfu.pdf for JUVÉDERM® Ultra Plus XC
    Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-ultra-xc_dfu.pdf for JUVÉDERM® Ultra XC

    Forward-Looking Statements
    Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

    Disclaimers
    Material developed and funded by Allergan Aesthetics, an AbbVie company.
    Copyright 2026 AbbVie. All rights reserved. All trademarks are the property of their respective owners.

    Footnotes

    †’Undetectable’ refers to an aesthetic aspiration towards subtle, natural-looking, and discreet outcomes, rather than a definitive result.

    ‡Based on a 30-minute online quantitative survey among aesthetics consumers across seven global markets. Respondents answered Q33: “When you think about ‘fillers’, how much do you agree or disagree with the following statements? Base: n=5306. Data labels <5% have been removed.2

    § Based on a 30-minute online quantitative survey conducted March–April 2025 across seven global markets. Respondents answered QB12b: “Which of these attributes / benefits do you associate with each of the following treatments? Base: physicians; n=575.2

    ‖ As perceived by HCPs.4

    ¶Based on HCP tracking market research involving over 1,700 HCPs from 16 international markets.6

    ††87%‡‡ TO 98%§§ SATISFACTION.17,21

    ‡‡In a clinical study of 192 patients treated with JUVÉDERM® VOLUMA® XC for correction of chin volume deficit, 87.3% of patients (n=110/126) rated their own appearance as improved or much improved six months after treatment.21

    §§In a clinical study of 60 patients treated with JUVÉDERM® VOLBELLA® XC for lip enhancement, 98.3% of patients (n=58/60) felt they had achieved improved lip fullness after one month.17

    ¶¶ In an in vivo study, a filler that has integrated with the tissue may give a natural look and feel.35

    **Tissue integration was demonstrated by JUVÉDERM® Ultra XC, JUVÉDERM® Ultra Plus XC, JUVÉDERM® VOLITE® XC, JUVÉDERM® VOLBELLA® XC, JUVÉDERM® VOLIFT® XC, JUVÉDERM® VOLUMA® XC, and JUVÉDERM® VOLUX® XC at one and four weeks in animal in vivo studies.36

    # In a study of patients aged ≥18 years treated with JUVÉDERM® VOLBELLA® XC in the lips, 65.1% (n=43) felt their lip results were “extremely natural or very natural.”37

    ΩResults lasting from nine months up to 24 months depending on the product used and facial areas treated.24-26

    References:

    1. Allergan Aesthetics. Data on file. REF-143204. The Future of HA Injectables. October 2025.
    2. Allergan Aesthetics. Data on file. REF-143192. HA Filler Future Global Results (slides from Integrated HCP & Consumer Reports). June 2025.
    3. Dayan S et al. Aesthet Surg J. 2019;39(12):1380–89.
    4. Chiu A et al. Clin Cosmet Investig Dermatol.2023;16:1521–32.
    5. Allergan Aesthetics. Data on file. REF-108642. JUVÉDERM®, The World’s Leading Brand of Hyaluronic Acid Facial Fillers Claim. March 2023.
    6. Allergan Aesthetics. Data on file. REF-99471. JUVÉDERM® Value Proposition Commercial Claims. August 2022.
    7. Juvéderm® VOLUX® XC Directions for Use. 73651JR10. Revision 2019-09-09.
    8. Juvéderm® VOLUMA® XC Directions for Use. 73650JR10. Revision 2019-09-09.
    9. Juvéderm® VOLIFT® XC Directions for Use. 73652JR10. Revision 2019-09-09.
    10. Juvéderm® VOLBELLA® XC 32G Directions for Use. 73363JR10. Revision 2020-07-10.
    11. Juvéderm® ULTRA 2 Directions for Use. 73661JR10. Revision 2019-09-09.
    12. Juvéderm® ULTRA 3 Directions for Use. 73662JR10. Revision 2019-09-09.
    13. Juvéderm® ULTRA 4 Directions for Use. 73663JR10. Revision 2019-09-09.
    14. Juvéderm® ULTRA SMILE Directions for Use. 73664JR10. Revision 2019-09-09.
    15. Allergan Aesthetics. Data on file. REF-96563. Fillers Global Number of Syringes. May 2022.
    16. Stephens H. 2000. Allergan’s First Fifty Years. Greenwich Pub. Lyme, Connecticut, USA.
    17. Eccleston D and Murphy DK. Clin Cosmet Investig Dermatol. 2012; 5:167–172.
    18. Philipp-Dormston WG et al. J Cosmet Laser Ther. 2014; 16:171–179.
    19. Ogilvie P et al. Dermatol Surg. 2019;45:1294–1303.
    20. Ogilvie P et al. Dermatol Surg. 2020;46:376–385.
    21. Beer K et al. Dermatol Surg. 2021;47:80–85.
    22. Dayan S et al. Dermatol Surg. 2015;41(Suppl 1): S293–301.
    23. Lanigan S. J Cosmet Dermatol. 2011; 10:11–14.
    24. Pinsky MA et al. Aesthetic Surg J. 2008;28:17–23.
    25. Callan P et al. Clin Cosmet Investig Dermatol. 2013; 6:81–89.
    26. Jones D and Murphy DK. Dermatol Surg. 2013;39:1602–1612.
    27. Wongprasert P et al. Dermatol Ther. 2022;35(6):e15453.
    28. Tran C et al. Dermatology. 2014;228(1):47–54.
    29. Allergan Aesthetics. Data on file. REF-114344. ABVRRTI79820 JUVÉDERM® Manufacturing and Quality Controls. July 2023.
    30. Kim JE and Sykes JM. Facial Plast Surg. 2011;276:523−528.
    31. Gutowski KA. Clin Plast Surg. 2016;43:489–496.
    32. Liew S et al. J Cosmet Dermatol. 2020;19:296–302.
    33. Dermatology Times, April 2025 (Vol. 46. No. 04). Dermatology Times, April 2025 (Vol. 46. No. 04). ‘The Undetectable Era’: How Patients Are Shifting Towards More Natural-Looking Results at the Clinic. Available at: https://www.dermatologytimes.com/view/-the-undetectable-era-how-patients-are-shifting-towards-more-natural-looking-results-at-the-clinic. Last accessed January 2026.
    34. Cosmopolitan. 13 Dec 2024. Available at: https://www.cosmopolitan.com/style-beauty/beauty/a63162072/lindsay-lohan-plastic-surgery/. Last accessed January 2026. 
    35. Hee CK et al. Dermatol Surg. 2015;41(Suppl 1):S373–S381.
    36. Allergan Aesthetics. Data on File. REF-140058. ABVRRT181526 JUVÉDERM® Vycross® and Hylacross® Tissue Integration Images. August 2025.
    37. Philipp-DormstonWG et al. J Cosmet Dermatol. 2014;13:125–134.
    38. Baumann LS et al. Dermatol Surg. 2007;33(Suppl. 2):S128–35.
    39. Allergan Aesthetics. Data on file. Holistic Beauty Global Research. REF-145017. January 2026.
    40. Lipko-Godlewska S et al. Clin Cosmet InvestigDermatol.2021;14:169–178.
    41. Fakih N et al. Facial Plast Surg. 2022;38:173−176.
    42. Heydenrych I, et al. Clin Cosmet Investig Dermatol. 2021;14:779-814. 
    43. Juvéderm® VOLITE® XC Directions for Use. 73655JR10. Revision 2019-09-09. 
    44. Juvéderm® Utra XC Directions for Use. 73659RX10. Revision 2019-09-09. 
    45. Juvéderm® Ultra Plus XC Directions for Use. 73660RX10. Revision 2019-09-09. 
    46. de la Guardia C et al. Facial Plast Surg. 2022;38(2):116–123. 
    47. Sánchez-Carpintero I et al. Actas Dermosifiliogr. 2010;101:381–393. 
    48. Walker K et al. 2022. Hyaluronic Acid. StatPearls. StatPearls Publishing. Treasure Island, Florida, USA. 
    49. Goodman GJ et al. Plast Reconstr Surg. 2015;136:S139–S148. 
    50. Kapoor KM et al. Clin Cosmet Investig Dermatol. 2021;14:1105–18.
    51. Ogilvie P et al. Aesthet Surg J. 2020;40: NP499–510.
    52. Dhillon B and Patel T. J Clin Aesthet Dermatol. 2020;13:33–40.
    53. Urdiales-Gálvez F et al. J Cosmet Dermatol. 2023;22(8):2186–97.
    54. Allergan Aesthetics. Data on file. HArmonyCaTM Lidocaine. Lift capacity. December 2024. 

    SOURCE AbbVie


    Continue Reading

  • Middle East conflict raises risks to growth in EBRD regions

    Middle East conflict raises risks to growth in EBRD regions

    • Higher energy and fertiliser costs expected to increase inflation and damp growth
    • Continued conflict could shave 0.4 percentage point off the EBRD’s growth forecast for its regions
    • Economies with high energy import bills, strong trade and remittance links to the Gulf particularly exposed

    The European Bank for Reconstruction and Development (EBRD) expects the conflict in the Middle East to weigh on economic activity across its regions by way of higher energy and fertiliser prices, disruptions to trade and tourism flows, and tighter financing conditions, according to its latest Regional Economic Update.

    Entitled “Potential economic impact of the conflict in the Middle East”, the new brief assesses how geopolitical tensions are being transmitted through commodity markets, supply chains and financial channels.

    “The conflict shows how quickly geopolitical shocks can ripple through energy markets, supply chains and financial conditions,” said Beata Javorcik, EBRD Chief Economist.

    “Rising energy prices come at an already challenging time for the European manufacturing sector, while the broader fallout from the conflict is likely to strain government budgets already overstretched by high defence spending in central Europe and elevated debt-servicing costs in the southern and eastern Mediterranean and sub-Saharan Africa. The effects of the conflict are likely to linger beyond the end of hostilities.”

    Energy prices have increased sharply as a result of recent disruptions to production and transport routes in the Persian Gulf. Even though oil and gas prices remain below historical peaks, short-term demand for energy is relatively inelastic and prices could rise significantly further should disruptions persist.

    The analysis notes that if oil remains above US$ 100 per barrel for a prolonged period and supply-chain disruptions involving chemicals and metals continue, global growth could be reduced by at least 0.4 percentage point, while inflation could rise by more than 1.5 percentage points. Under such a scenario, growth forecasts for the EBRD regions could be cut by up to 0.4 percentage point in the Bank’s next outlook.

    Gas markets remain tight, with European storage levels significantly below those seen in recent years. Even if the conflict ends quickly, prices may remain elevated as buyers rebuild inventories, because liquified natural gas (LNG) production will take time to resume.

    The impact is also being felt in agricultural inputs and industrial supply chains. A significant share of global trade in fertiliser raw materials passes through the Strait of Hormuz, raising the risk of higher food prices. Disruptions to Gulf trade routes may also affect key inputs, such as aluminium, sulphur, helium, petrochemicals and plastics, adding to global inflationary pressures.

    Trade with the Gulf Cooperation Council (GCC) is significant for many economies in the EBRD regions, while direct trade with Iran remains limited. Economies reliant on routes through the Strait of Hormuz, including Iraq, may face particular challenges, although existing reserves of key commodities, such as wheat, provide some buffer.

    The update notes that tourism and remittances are additional transmission channels. Tourism-dependent economies, such as Jordan, are likely to see a decline in visitor arrivals, while remittances from GCC countries – an important source of income for economies including Lebanon, Jordan and Egypt – may come under pressure.

    Financial conditions have also tightened, with bond yields rising in the southern and eastern Mediterranean region and in Türkiye. Capital outflows from some economies have so far remained manageable, but could intensify if global financial conditions deteriorate further.

    The extent to which economies can cushion the terms-of-trade shocks will depend on their fiscal and external buffers.

    EBRD economies with high energy, fertiliser and food import dependence, strong links to the Gulf and limited fiscal space are likely to be most affected. These include Egypt, Iraq, Jordan, Kenya, Lebanon, Moldova, Mongolia, North Macedonia, Senegal, Tunisia, Türkiye and Ukraine.

    In the longer term, the conflict may reinforce the importance of energy security and accelerate the fragmentation of global trade, particularly in energy and critical raw materials. At the same time, higher energy prices are already generating windfall revenues for commodity exporters, including Russia.

    The EBRD stands ready to support its clients and countries of operation in addressing the economic impact of current developments in the Middle East.

    Continue Reading

  • Transcript: Investors try to stay ahead of Trump’s Iran moves – Financial Times

    1. Transcript: Investors try to stay ahead of Trump’s Iran moves  Financial Times
    2. Oil traders bet millions ahead of Trump’s Iran talks post  BBC
    3. Futures Markets Saw Trading Spike Before Trump’s Iran Post  Bloomberg.com
    4. Oil, stock trading spiked before Trump’s Iran remarks: media  Dawn
    5. Traders placed $580mn in oil bets ahead of Donald Trump’s social media post on Iran talks  Financial Times

    Continue Reading

  • Trump Says the Energy Shock Will Be Short-Lived. CEOs Paint a Scarier Picture. – WSJ

    1. Trump Says the Energy Shock Will Be Short-Lived. CEOs Paint a Scarier Picture.  WSJ
    2. CERAWEEK: US SPR to release at rate of 1 million-1.5 million b/d: Wright  S&P Global
    3. White House’s ‘Drill Baby Drill’ Wartime Mandate Meets Volatile Market Reality  Inside Climate News
    4. The United States officially begins to draw from strategic oil reserves  المتداول العربي
    5. CNBC Transcript: U.S. Energy Secretary Chris Wright Speaks with CNBC’s Brian Sullivan on “Squawk on the Street” Today  CNBC

    Continue Reading